Japan fund backs neglected disease R&D
This article was originally published in Scrip
Executive Summary
Eisai, Merck KGaA and Astellas Pharma are the among the private sector players that have been granted new funding from the Japanese Global Health Innovative Technology Fund (GHIT Fund) for a clutch of neglected diseases.